(NASDAQ:UNCY) NEW YORK, Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certain officers. The class action, filed in the United States District Court Northern District...
Related Questions
What potential downside risk does the class action pose to UNCY's share price if it results in a significant settlement or judgment?
How could the allegations against corporate officers affect Unicycive's governance stability and ability to raise capital?
What have been the market reactions and valuation impacts in similar biotech class action cases, and could this trigger increased short‑selling activity?